|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,792.90 INR | +0.65% |
|
+0.41% | -4.95% |
| Dec. 12 | Indian Stocks Extend Gains on Friday as Global Sentiment Improves After US Rate Cut | MT |
| Dec. 12 | Ozempic launches in India at $24 a week as Novo targets booming diabetes market | RE |
| Capitalization | 4,274B 47.01B 39.93B 37.35B 35.01B 64.62B 70.82B 436B 168B 2,008B 176B 173B 7,278B | P/E ratio 2026 * |
38.2x | P/E ratio 2027 * | 32.1x |
|---|---|---|---|---|---|
| Enterprise value | 4,057B 44.63B 37.9B 35.46B 33.24B 61.34B 67.23B 414B 160B 1,906B 167B 164B 6,909B | EV / Sales 2026 * |
7.07x | EV / Sales 2027 * | 6.26x |
| Free-Float |
44.9% | Yield 2026 * |
0.82% | Yield 2027 * | 0.92% |
Last Transcript: Sun Pharmaceutical Industries Ltd.
| 1 day | +0.65% | ||
| 1 week | +0.41% | ||
| Current month | -2.11% | ||
| 1 month | +1.64% | ||
| 3 months | +10.66% | ||
| 6 months | +8.65% | ||
| Current year | -4.95% |
| 1 week | 1,771.5 |  | 1,811.8 |
| 1 month | 1,750 | | 1,849 |
| Current year | 1,548 | | 1,896 |
| 1 year | 1,548 | | 1,910 |
| 3 years | 922.45 | | 1,960.35 |
| 5 years | 539.7 | | 1,960.35 |
| 10 years | 312 | | 1,960.35 |
| Manager | Title | Age | Since |
|---|---|---|---|
Aalok Shanghvi
CEO | Chief Executive Officer | - | - |
| Chief Executive Officer | 58 | 2025-08-31 | |
| Director of Finance/CFO | 57 | 2025-06-30 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 69 | - | |
| Director/Board Member | 73 | 2018-05-24 | |
| Director/Board Member | 70 | 2021-05-20 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.65% | +0.41% | +0.22% | +81.48% | 47.01B | |
| +0.53% | -0.92% | +7.23% | +105.04% | 31.32B | |
| +0.78% | -3.32% | +54.18% | - | 30.63B | |
| -0.18% | +0.40% | +3.17% | +36.50% | 13.32B | |
| +0.41% | -0.60% | -5.34% | +124.34% | 10.12B | |
| -0.55% | -8.04% | +69.76% | +74.02% | 8.9B | |
| -2.28% | -3.75% | +38.99% | +107.88% | 6.9B | |
| -.--% | +0.14% | - | - | 6.79B | |
| +0.11% | +0.16% | +34.40% | -35.06% | 6.67B | |
| -0.92% | -0.12% | +28.68% | +367.52% | 6.1B | |
| Average | -0.14% | -0.98% | +25.70% | +107.71% | 16.78B | |
| Weighted average by Cap. | +0.29% | -1.04% | +19.75% | +94.19% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 574B 6.31B 5.36B 5.01B 4.7B 8.67B 9.51B 58.57B 22.6B 270B 23.67B 23.18B 977B | 634B 6.97B 5.92B 5.54B 5.19B 9.59B 10.51B 64.73B 24.97B 298B 26.16B 25.62B 1,080B |
| Net income | 112B 1.23B 1.05B 978M 916M 1.69B 1.85B 11.42B 4.41B 52.56B 4.62B 4.52B 191B | 134B 1.47B 1.25B 1.17B 1.09B 2.02B 2.21B 13.64B 5.26B 62.77B 5.51B 5.4B 228B |
| Net Debt | -217B -2.39B -2.03B -1.9B -1.78B -3.28B -3.59B -22.15B -8.54B -102B -8.95B -8.76B -369B | -307B -3.38B -2.87B -2.69B -2.52B -4.65B -5.09B -31.37B -12.1B -144B -12.68B -12.41B -523B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 25-12-17 | 1,792.90 ₹ | +0.65% | 1,910,628 |
| 25-12-16 | 1,781.30 ₹ | -0.88% | 1,533,979 |
| 25-12-15 | 1,797.10 ₹ | +0.20% | 1,396,948 |
| 25-12-12 | 1,793.50 ₹ | -0.76% | 1,442,309 |
| 25-12-11 | 1,807.20 ₹ | +1.22% | 1,280,916 |
Delayed Quote NSE India S.E., December 17, 2025 at 06:49 am EST
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- SUNPHARMA Stock
Select your edition
All financial news and data tailored to specific country editions
